— Know what they know.
Not Investment Advice

DRNA NASDAQ

Dicerna Pharmaceuticals, Inc.
1W: +1.1% 1M: +0.6% 3M: +83.3% 1Y: +63.1% 3Y: +263.6% 5Y: +1153.1%
$38.22
Last traded 2021-12-27 — delisted
NASDAQ · Healthcare · Biotechnology

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

WEAK EDGE
48.6 / 100
NoneWeakNarrowWide
Primary source: Cost Advantage  ·  ROIC: 24.4%
Cost Advantage ★
58
Intangibles
45
Switching Cost
47
Network Effect
53
Scale
40
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. DRNA shows a Weak competitive edge (48.6/100) — limited structural advantages that may face competitive pressure. The primary source of advantage is Cost Advantage. ROIC of 24.4% confirms the company is generating returns well above its cost of capital — a hallmark of durable competitive advantages.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
Analyst Recommendations
Strong Buy: 0Buy: 11Hold: 6Sell: 0Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$—
Analysts0

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 26 Grade D
Profitability
20
Balance Sheet
0
Earnings Quality
39
Growth
65
Value
27
Momentum
61
Safety
15
Cash Flow
24
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. DRNA scores highest in Growth (65/100) and lowest in Balance Sheet (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
0.52
Distress Zone
Piotroski F-Score
3/9
✗ ✓ ✗ ✓ ✗ ✗ ✗ ✗ ✓
Beneish M-Score
-1.24
Possible Manipulator
Ohlson O-Score
-4.45
Bankruptcy prob: 1.2%
Low Risk
Credit Rating
BB-
Score: 36.3/100
Trend: Deteriorating
Earnings Quality
—
OCF/NI: -0.17x
Accruals: -20.0%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. DRNA scores 0.52, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. DRNA scores 3/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. DRNA's score of -1.24 exceeds the −1.78 red flag threshold — this does not confirm manipulation but indicates the earnings profile resembles past manipulators statistically. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. DRNA's implied 1.2% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. DRNA receives an estimated rating of BB- (score: 36.3/100), with a deteriorating trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-25.31x
PEG
10.74x
P/S
0.00x
P/B
20.68x
P/FCF
183.17x
P/OCF
74.46x
EV/EBITDA
-9.00x
EV/Revenue
5.53x
EV/EBIT
-12.33x
EV/FCF
124.61x
Earnings Yield
-7.94%
FCF Yield
0.55%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. DRNA currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
1.011
NI / EBT
×
Interest Burden
1.423
EBT / EBIT
×
EBIT Margin
-0.448
EBIT / Rev
×
Asset Turnover
0.265
Rev / Assets
×
Equity Multiplier
5.562
Assets / Equity
=
ROE
-95.2%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. DRNA's ROE of -95.2% is driven by financial leverage (equity multiplier: 5.56x). Note: high leverage means ROE is amplified by debt rather than operational performance. A tax burden ratio of 1.01 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$38.22
Median 1Y
$35.60
5th Pctile
$11.87
95th Pctile
$106.60
Ann. Volatility
73.6%
25th–75th percentile 5th–95th percentile Median path Historical
All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
ROE -90.0% -1.1% -1.5% -2.4% -84.3% -1.1% -2.1% -1.1% -58.9% -74.3% -78.0% -68.4% -68.3% -65.3% -77.4% -80.4% -77.8% -79.0% -94.6% -95.2% -95.22%
ROA -78.7% -92.8% -68.2% -80.3% -69.8% -85.6% -88.8% -64.0% -33.5% -40.7% -38.9% -38.1% -23.9% -20.1% -22.8% -22.8% -17.3% -16.4% -16.5% -17.1% -17.12%
ROIC 10.1% 12.2% 60.6% 58.4% 3.8% 4.9% 5.4% 2.0% 49.9% 32.2% 38.6% 47.7% 58.5% 19.6% 21.6% 22.3% 23.6% 25.2% 23.5% 24.4% 24.35%
ROCE -1.4% -2.0% -68.0% -60.5% -28.4% -17.2% -48.3% -34.7% -23.1% -23.5% -14.0% -8.5% -11.2% -11.8% -19.8% -21.3% -10.2% -12.3% -11.1% -16.2% -16.23%
Gross Margin 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.00%
Operating Margin -105.8% -107.1% -61.0% -32.1% -11.1% -10.3% -8.8% -10.0% -12.6% -9.1% -4.6% -4.1% -5.8% -74.0% -82.8% -46.9% -77.3% -61.1% -97.4% -32.2% -32.20%
Net Margin -105.4% -106.8% -60.4% -31.7% -11.0% -10.1% -23.1% -12.3% -12.1% -8.4% -4.2% -3.8% -5.6% -66.1% -78.7% -44.7% -89.3% -62.9% -98.7% -27.1% -27.12%
EBITDA Margin -103.8% -105.6% -59.6% -31.3% -10.8% -10.0% -22.8% -12.0% -11.8% -8.3% -4.1% -3.8% -5.5% -64.5% -77.3% -43.6% -87.9% -61.2% -93.4% -23.5% -23.52%
FCF Margin -166.8% -111.8% -74.0% -51.6% -20.0% -13.3% -10.2% -8.2% 2.9% 13.5% 7.8% 3.8% -29.5% 4.4% 2.5% 1.5% 99.4% -1.0% 6.3% 4.4% 4.44%
OCF Margin -165.2% -111.0% -73.7% -51.4% -19.9% -13.2% -10.2% -8.1% 3.0% 13.8% 8.2% 4.1% -2.9% 4.5% 2.6% 1.6% 1.1% -97.1% 15.6% 10.9% 10.92%
ROE 3Y Avg snapshot only -88.31%
ROA 3Y Avg snapshot only -20.89%
ROIC Economic snapshot only -56.95%
Cash ROA snapshot only 2.73%
NOPAT Margin snapshot only -49.68%
Pretax Margin snapshot only -63.82%
R&D / Revenue snapshot only 1.18%
SGA / Revenue snapshot only 44.96%
SBC / Revenue snapshot only 24.30%
Valuation
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
P/E Ratio -1.00 -1.22 -1.15 -2.05 -3.13 -8.05 -7.87 -9.74 -7.61 -10.06 -12.28 -9.88 -12.58 -11.47 -15.06 -11.57 -14.56 -16.22 -22.25 -12.60 -25.311
P/S Ratio 202.61 165.17 97.16 120.81 82.65 134.04 129.23 138.15 109.51 129.23 90.62 53.45 63.37 24.43 20.98 10.28 9.99 10.96 16.08 8.13 0.000
P/B Ratio 1.45 2.43 4.98 -31.71 1.86 5.63 9.97 5.35 3.37 5.57 6.72 7.31 9.95 7.53 11.59 8.72 11.92 15.43 25.88 14.56 20.677
P/FCF -1.21 -1.48 -1.31 -2.34 -4.14 -10.10 -12.64 -16.88 37.70 9.57 11.60 13.94 -215.15 5.52 8.29 6.74 10.05 -10.46 256.38 183.17 183.170
P/OCF — — — — — — — — 36.96 9.34 11.12 12.94 — 5.40 8.08 6.46 9.38 — 103.32 74.46 74.460
EV/EBITDA -0.24 -0.66 0.40 -0.76 -1.26 -6.54 -7.05 -7.75 -4.27 -6.45 -8.50 -6.84 -9.98 -5.70 -10.03 -6.61 -10.18 -12.37 -18.77 -9.00 -8.996
EV/Revenue 47.10 88.36 -33.33 44.28 32.73 107.52 114.49 108.35 60.51 81.66 61.77 36.55 49.76 11.97 13.76 5.77 6.85 8.19 13.13 5.53 5.529
EV/EBIT -0.23 -0.65 0.39 -1.01 -2.52 -25.81 -16.08 -12.09 -5.14 -8.70 -19.72 -36.46 -29.99 -10.56 -13.12 -8.01 -20.72 -23.58 -33.42 -12.33 -12.329
EV/FCF -0.28 -0.79 0.45 -0.86 -1.64 -8.10 -11.20 -13.24 20.83 6.05 7.91 9.53 -168.93 2.70 5.44 3.78 6.89 -7.81 209.30 124.61 124.611
Earnings Yield -99.6% -82.1% -87.2% -48.8% -31.9% -12.4% -12.7% -10.3% -13.1% -9.9% -8.1% -10.1% -8.0% -8.7% -6.6% -8.6% -6.9% -6.2% -4.5% -7.9% -7.94%
FCF Yield -82.3% -67.7% -76.2% -42.7% -24.2% -9.9% -7.9% -5.9% 2.7% 10.5% 8.6% 7.2% -0.5% 18.1% 12.1% 14.8% 10.0% -9.6% 0.4% 0.5% 0.55%
PEG Ratio snapshot only 10.735
Price/Tangible Book snapshot only 14.558
EV/OCF snapshot only 50.655
EV/Gross Profit snapshot only 5.529
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Current Ratio 4.76 3.50 9.57 7.59 7.12 6.95 5.40 6.30 4.31 5.00 3.65 2.68 2.30 2.90 2.63 2.62 3.48 3.26 2.97 2.46 2.461
Quick Ratio 4.76 3.50 9.57 7.59 7.12 6.95 5.40 6.30 4.31 5.00 3.65 2.68 2.30 2.90 2.63 2.62 3.48 3.26 2.97 2.46 2.461
Debt/Equity 0.00 0.00 0.00 -0.00 0.00 0.00 0.14 0.00 0.00 0.02 0.02 0.02 0.15 0.13 0.14 0.14 0.38 0.41 0.59 0.60 0.598
Net Debt/Equity -1.11 -1.13 -6.69 — -1.12 -1.11 -1.14 -1.15 -1.51 -2.05 -2.14 -2.31 -2.14 -3.84 -3.99 -3.83 -3.75 -3.90 -4.75 -4.65 -4.654
Debt/Assets 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.00 0.01 0.01 0.01 0.04 0.03 0.03 0.03 0.07 0.08 0.08 0.08 0.083
Debt/EBITDA -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.11 -0.00 -0.00 -0.03 -0.03 -0.02 -0.20 -0.21 -0.18 -0.19 -0.47 -0.44 -0.52 -0.54 -0.544
Net Debt/EBITDA 0.78 0.57 1.56 1.32 1.92 1.61 0.91 2.13 3.46 3.76 3.97 3.16 2.73 5.93 5.26 5.17 4.67 4.19 4.22 4.23 4.228
Interest Coverage — — — — — — -201.52 -136.00 -120.52 -120.52 -87.13 -90.23 -13222.33 -8879.29 -7228.38 -7228.38 -5430.20 -6177.50 -8778.25 -7207.00 -7207.000
Equity Multiplier 1.24 1.36 7.14 -21.89 1.19 1.18 1.39 1.19 2.04 2.14 2.26 2.50 3.93 4.38 4.52 4.44 5.14 5.41 7.55 7.17 7.171
Cash Ratio snapshot only 2.363
Debt Service Coverage snapshot only -9877.333
Cash to Debt snapshot only 8.778
FCF to Debt snapshot only 0.133
Defensive Interval snapshot only 664.3 days
Efficiency & Turnover
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Asset Turnover 0.00 0.01 0.01 0.01 0.03 0.05 0.05 0.05 0.02 0.03 0.05 0.07 0.05 0.09 0.16 0.26 0.25 0.24 0.23 0.27 0.265
Inventory Turnover — — — — — — — — — — — — — — — — — — — — —
Receivables Turnover 0.94 — — — 1.54 4.66 6.29 — 0.12 9.78 15.00 12.24 0.16 7.31 133.82 29.05 1.38 7.69 56.27 31.60 31.597
Payables Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
DSO 387 0 0 0 238 78 58 0 3050 37 24 30 2313 50 3 13 265 47 6 12 11.6 days
DIO — — — — — — — — — — — — — — — — — — — — —
DPO — — — — — — — — — — — — — — — — — — — — —
Cash Conversion Cycle — — — — — — — — — — — — — — — — — — — — —
Fixed Asset Turnover snapshot only 2.040
Cash Velocity snapshot only 0.341
Capital Intensity snapshot only 4.003
Growth (YoY)
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Revenue 60.3% 1.3% — 5.1% 6.7% 7.6% 6.3% 5.1% 1.7% 1.1% 1.4% 2.0% 2.9% 6.1% 6.5% 6.1% 5.9% 2.2% 99.5% 47.9% 47.86%
Net Income 5.3% 10.0% 9.8% 4.3% -0.9% -5.9% -42.0% -46.8% -48.0% -61.9% -7.1% -15.8% -35.6% -17.5% -42.4% -16.5% 6.4% -2.9% -3.6% -7.4% -7.43%
EPS 6.0% 10.6% 10.3% 4.7% -0.5% 57.4% 43.7% 44.2% 51.3% -22.7% 17.6% 7.2% -24.7% -10.0% -31.5% -6.9% 13.6% 1.6% 0.5% -3.0% -2.98%
FCF 1.5% 10.1% 4.9% -0.4% 7.6% -2.3% -1.2% 3.2% 1.4% 3.1% 2.8% 2.4% -1.4% 1.3% 1.4% 1.8% 24.2% -1.8% -95.1% -95.7% -95.70%
EBITDA 5.5% 10.1% 9.9% 4.3% -1.0% -5.9% -42.3% -46.7% -47.6% -61.7% -6.7% -15.9% -36.3% -17.6% -42.5% -16.0% 7.3% -2.1% -1.7% -4.1% -4.13%
Op. Income 5.2% 9.9% 9.7% 4.0% -1.4% -6.8% -4.3% -3.1% -6.3% -23.3% -47.6% -75.1% -99.0% -63.2% -48.9% -15.6% 11.7% 6.4% 6.6% 1.3% 1.34%
OCF Growth snapshot only -89.85%
Asset Growth snapshot only 13.25%
Equity Growth snapshot only -29.95%
Debt Growth snapshot only 1.98%
Shares Change snapshot only 4.33%
Growth (CAGR)
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Revenue 3Y — — — — — — 2.0% 2.2% 2.2% 2.5% — 3.8% 3.3% 4.0% 4.1% 4.1% 3.2% 2.6% 2.3% 2.2% 2.17%
Revenue 5Y — — — — — — — — — — — — — — 2.4% 2.7% 2.9% 3.0% — 3.1% 3.12%
EPS 3Y — — — — — — — — — — — — — — — — — — — — —
EPS 5Y — — — — — — — — — — — — — — — — — — — — —
Net Income 3Y — — — — — — — — — — — — — — — — — — — — —
Net Income 5Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 3Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 5Y — — — — — — — — — — — — — — — — — — — — —
Gross Profit 3Y — — — — — — 2.0% 2.2% 2.2% 2.5% — 3.8% 3.3% 4.0% 4.1% 4.1% 3.2% 2.6% 2.3% 2.2% 2.17%
Gross Profit 5Y — — — — — — — — — — — — — — 2.4% 2.7% 2.9% 3.0% — 3.1% 3.12%
Op. Income 3Y — — — — — — — — — — — — — — — — — — — — —
Op. Income 5Y — — — — — — — — — — — — — — — — — — — — —
FCF 3Y — — — — — — — — — — — — — — — — — — — — —
FCF 5Y — — — — — — — — — — — — — — — — — — — — —
OCF 3Y — — — — — — — — — — — — — — — — — — — — —
OCF 5Y — — — — — — — — — — — — — — — — — — — — —
Assets 3Y — -33.8% -8.6% -10.7% 5.3% 3.9% -11.1% 17.7% 59.9% 65.0% 69.4% 74.8% 1.3% 1.7% 97.7% 1.0% 80.2% 87.3% 1.1% 60.9% 60.85%
Assets 5Y — — — — — — — — — 23.1% 23.8% 23.7% 42.0% 53.0% 41.8% 43.1% 47.9% 51.5% 62.4% 65.1% 65.09%
Equity 3Y — -39.2% -52.0% — 1.0% 0.4% -18.4% 14.5% 30.2% 32.0% 35.1% 36.2% 54.6% 82.9% 1.3% — 10.8% 12.9% 19.8% -11.7% -11.70%
Book Value 3Y — -51.1% -54.6% — -4.2% -29.6% -42.0% -17.4% -10.5% -11.4% -9.2% -8.4% 3.7% 20.4% 51.0% — -27.5% -0.8% 5.5% -21.4% -21.42%
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Revenue Stability 0.98 0.87 0.56 0.73 0.71 0.70 0.68 0.71 0.85 0.69 0.67 0.63 0.61 0.52 0.51 0.51 0.51 0.61 0.71 0.75 0.746
Earnings Stability 0.55 0.69 0.61 0.50 0.42 0.60 0.78 0.75 0.68 0.77 0.84 0.85 0.78 0.78 0.81 0.85 0.80 0.84 0.90 0.95 0.953
Margin Stability — — — 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Rev. Growth Consistency 1.00 1.00 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
Earn. Growth Consistency 0.50 0.50 0.50 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.00 0.00 0.00 0.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 1 1
Earnings Persistence 0.98 0.96 0.96 0.98 1.00 0.98 0.83 0.81 0.81 0.50 0.97 0.94 0.86 0.93 0.83 0.93 0.97 0.99 0.99 0.97 0.970
Earnings Smoothness — — — — — — — — — — — — — — — — — — — — —
ROE Trend -0.86 -1.29 -3.62 — 0.47 0.71 1.40 — 0.58 0.79 2.26 — -0.27 -0.03 0.14 -0.11 -0.20 -0.35 -0.51 -0.41 -0.409
Gross Margin Trend — — — 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000
FCF Margin Trend — — — 241.11 199.11 187.34 — 174.83 96.27 76.07 49.93 33.72 8.24 4.31 3.74 3.70 -0.31 -10.02 -5.11 -2.64 -2.636
Sustainable Growth Rate — — — — — — — — — — — — — — — — — — — — —
Internal Growth Rate — — — — — — — — — — — — — — — — — — — — —
Cash Flow Quality
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
OCF/Net Income 0.82 0.82 0.87 0.87 0.75 0.79 0.62 0.57 -0.21 -1.08 -1.10 -0.76 0.01 -2.12 -1.86 -1.79 -1.55 1.44 -0.22 -0.17 -0.169
FCF/OCF 1.01 1.01 1.00 1.00 1.00 1.00 1.00 1.00 0.98 0.98 0.96 0.93 10.17 0.98 0.97 0.96 0.93 1.08 0.40 0.41 0.407
FCF/Net Income snapshot only -0.069
CapEx/Revenue 1.5% 88.8% 33.5% 20.9% 5.8% 5.7% 5.0% 4.0% 5.8% 32.4% 34.0% 29.6% 26.6% 9.9% 6.5% 6.5% 7.1% 7.7% 9.3% 6.5% 6.48%
CapEx/Depreciation snapshot only 2.751
Accruals Ratio -0.14 -0.17 -0.09 -0.10 -0.17 -0.18 -0.34 -0.27 -0.40 -0.85 -0.82 -0.67 -0.24 -0.63 -0.65 -0.64 -0.44 0.07 -0.20 -0.20 -0.200
Sloan Accruals snapshot only -0.059
Cash Flow Adequacy snapshot only 1.685
Dividends & Buybacks
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — — — — — — — — — — — — — —
FCF Payout Ratio — — — — — — — — 0.0% 0.0% 0.0% 0.0% — 0.0% 0.0% 0.0% 0.0% — 0.0% 0.0% 0.00%
Total Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Div. Increase Streak — — — — — — — — — — — — — — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -8.9% -6.0% -5.6% -6.2% -3.0% -6.3% -4.5% -6.3% 0.0% -2.0% -1.4% -2.5% -2.50%
Total Shareholder Return 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -8.9% -6.0% -5.6% -6.2% -3.0% -6.3% -4.5% -6.3% 0.0% -2.0% -1.4% -2.5% -2.50%
DuPont Factors
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Tax Burden (NI/EBT) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.01 1.011
Interest Burden (EBT/EBIT) 1.00 1.00 0.99 1.34 2.03 4.00 2.31 1.58 1.22 1.37 2.36 5.40 3.04 1.88 1.33 1.23 2.08 1.95 1.83 1.42 1.423
EBIT Margin -202.54 -136.07 -85.17 -44.03 -13.00 -4.17 -7.12 -8.96 -11.77 -9.39 -3.13 -1.00 -1.66 -1.13 -1.05 -0.72 -0.33 -0.35 -0.39 -0.45 -0.448
Asset Turnover 0.00 0.01 0.01 0.01 0.03 0.05 0.05 0.05 0.02 0.03 0.05 0.07 0.05 0.09 0.16 0.26 0.25 0.24 0.23 0.27 0.265
Equity Multiplier 1.14 1.17 2.16 2.95 1.21 1.23 2.37 1.76 1.76 1.82 2.01 1.79 2.85 3.25 3.39 3.53 4.50 4.80 5.75 5.56 5.562
Per Share
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
EPS (Diluted TTM) $-2.87 $-2.79 $-2.76 $-2.81 $-2.88 $-1.19 $-1.56 $-1.57 $-1.40 $-1.46 $-1.28 $-1.45 $-1.75 $-1.60 $-1.69 $-1.55 $-1.51 $-1.58 $-1.68 $-1.60 $-1.60
Book Value/Share $1.99 $1.40 $0.64 $-0.18 $4.86 $1.70 $1.23 $2.85 $3.17 $2.63 $2.34 $1.97 $2.21 $2.44 $2.19 $2.06 $1.85 $1.66 $1.44 $1.38 $1.85
Tangible Book/Share $1.99 $1.40 $0.64 $-0.18 $4.86 $1.70 $1.23 $2.85 $3.17 $2.63 $2.34 $1.97 $2.21 $2.44 $2.19 $2.06 $1.85 $1.66 $1.44 $1.38 $1.38
Revenue/Share $0.01 $0.02 $0.03 $0.05 $0.11 $0.07 $0.09 $0.11 $0.10 $0.11 $0.17 $0.27 $0.35 $0.75 $1.21 $1.75 $2.20 $2.33 $2.32 $2.48 $2.20
FCF/Share $-2.37 $-2.30 $-2.41 $-2.46 $-2.18 $-0.95 $-0.97 $-0.90 $0.28 $1.53 $1.36 $1.03 $-0.10 $3.33 $3.06 $2.67 $2.19 $-2.44 $0.15 $0.11 $2.19
OCF/Share $-2.35 $-2.28 $-2.40 $-2.45 $-2.17 $-0.94 $-0.96 $-0.90 $0.29 $1.57 $1.42 $1.11 $-0.01 $3.40 $3.14 $2.78 $2.35 $-2.26 $0.36 $0.27 $2.35
Cash/Share $2.21 $1.58 $4.26 $3.64 $5.45 $1.89 $1.57 $3.29 $4.78 $5.44 $5.05 $4.57 $5.07 $9.69 $9.04 $8.18 $7.63 $7.15 $7.70 $7.27 $7.63
EBITDA/Share $-2.83 $-2.75 $-2.73 $-2.77 $-2.84 $-1.17 $-1.54 $-1.54 $-1.38 $-1.44 $-1.26 $-1.44 $-1.73 $-1.58 $-1.66 $-1.53 $-1.48 $-1.54 $-1.62 $-1.52 $-1.52
Debt/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.17 $0.00 $0.00 $0.05 $0.04 $0.03 $0.34 $0.32 $0.31 $0.29 $0.70 $0.68 $0.85 $0.83 $0.83
Net Debt/Share $-2.21 $-1.58 $-4.26 $-3.64 $-5.45 $-1.89 $-1.40 $-3.29 $-4.78 $-5.39 $-5.01 $-4.54 $-4.73 $-9.37 $-8.74 $-7.89 $-6.93 $-6.47 $-6.85 $-6.45 $-6.45
Academic Models
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — 0.523
Altman Z-Prime snapshot only 1.631
Piotroski F-Score 2 2 4 4 4 4 2 3 4 3 4 4 2 4 4 4 5 2 5 3 3
Beneish M-Score — — — -1.13 5.06 6.48 0.49 -1.36 31.09 -4.63 -3.03 0.91 0.46 4.71 1.24 -0.57 -0.33 -1.28 2.36 -1.24 -1.238
Ohlson O-Score snapshot only -4.449
ROIC (Greenblatt) snapshot only -19.47%
Net-Net WC snapshot only $-0.97
Credit
Metric Trend Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Q3'18 Q4'18 Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Q2'20 Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Current
Credit Rating snapshot only BB-
Credit Score 60.17 59.82 60.12 20.00 77.71 89.00 61.35 67.14 40.21 48.58 54.06 49.68 40.10 45.42 48.42 43.33 41.74 37.95 41.44 36.27 36.273
Credit Grade snapshot only 13
Credit Trend snapshot only -7.054
Implied Spread (bps) snapshot only 550.000
Industry Credit Rank snapshot only 23
Sector Credit Rank snapshot only 24

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms